AZD4045 for Multiple Myeloma

This trial tests a new treatment called AZD4045 for individuals with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer. The study aims to assess the safety and effectiveness of AZD4045 both alone and in combination with other treatments like daratumumab and aldesleukin. It seeks participants who have previously tried at least three different treatment types and meet specific disease criteria, such as having certain protein levels in their blood or urine linked to multiple myeloma. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

A previous study tested AZD4045 for safety in patients with multiple myeloma. The results showed that AZD4045 is generally safe, with no reports of serious side effects like cytokine release syndrome (CRS) or nerve damage, which can sometimes occur with cancer treatments.

When combined with the drugs daratumumab and aldesleukin, AZD4045 maintained a safety profile similar to daratumumab used alone. Daratumumab is usually safe, but some patients might experience fatigue, nausea, or headaches. Serious reactions are rare but possible.

Most treatments for multiple myeloma, such as proteasome inhibitors and immunomodulatory drugs, work by disrupting cancer cell growth and survival. However, AZD4045 is unique because it uses a novel mechanism to specifically target and disrupt pathways critical for myeloma cell survival. This targeted action could potentially improve effectiveness and reduce side effects compared to current therapies. Moreover, when combined with daratumumab and aldesleukin, AZD4045 might enhance immune response against the cancer, offering a potentially powerful new approach for patients. Researchers are excited about these possibilities because they represent a significant step forward in personalized cancer therapy.

Research has shown that AZD4045 holds promise for treating multiple myeloma, a type of blood cancer. One study found that 96% of patients responded to AZD4045, with 85% achieving a complete response, meaning their cancer was not detectable. In this trial, participants may receive AZD4045 as a monotherapy or in combination with daratumumab and aldesleukin. Treatments with daratumumab have been shown to lower the risk of cancer progression and extend patient survival. These findings suggest that AZD4045, whether used alone or with other treatments, could be effective for people with multiple myeloma.⁴⁶⁷⁸⁹